Clinical Trials and Research
Ramsay is proud to play a leading role in Australia’s health and medical research sector by driving research through the
Ramsay Research & Development Network,
the Ramsay Hospital Research Foundation,
and our Research Ethics, and
Research Governance Unit.
The Clinical Trials and Research Unit at Joondalup Health Campus is part of the Ramsay Research & Development Network that operates across 20+ Ramsay Health Care facilities throughout Australia.
Our hospital actively encourages and supports clinical research as a key contributor to improved patient outcomes. We believe that providing early access to promising clinical trials is essential to delivering
high-quality, leading-edge care; consistent with the standard of care at our hospital.
In an era of rapid medical innovation and evolving healthcare demands, research remains the foundation of excellence, progress, and improved patient care. The
Joondalup Health Campus Research Strategic Plan 2025–2030
sets out our vision and priorities for cultivating a vibrant research culture aligned with our commitment to delivering world-class healthcare.
By establishing clear goals and measurable outcomes, we will ensure our research efforts are focused, transparent, and aligned with both local priorities and global standards.
Together, we move forward—transforming care through discovery, innovation, collaboration, and translation.
Conducting Research
Our hospital has a dedicated clinical trials & research unit that supports the conduct of research across all aspects of the hospital. Our site manager and the broader research team can provide advice on how to get involved.
For any inquiries, please contact Joanna Brisbane, Joondalup Health Campus Research & Clinical Trials Manager
Ph: (08) 9400 9897
Email: ClinicalTrials.JHC@ramsayhealth.com.au
Participating in Research
If you’re interested in participating in a clinical trial, you may be eligible for one currently being conducted at Joondalup Health Campus, as listed below. Please speak with your doctor to explore your options.
If you’re interested in participating in a clinical trial, which is not offered at Joondalup Health Campus, your doctor may be able to help you find another trial that is suitable for you. Alternatively, you can search for suitable clinical trials through the
Australian Clinical Trials website or
ClinTrial Refer.
For any enquiries, please contact Joanna Brisbane, Joondalup Health Campus Research & Clinical Trials Manager
Ph: (08) 9400 9897
Email: ClinicalTrials.JHC@ramsayhealth.com.au
Clinical Trials Joondalup Health Campus
| Therapeutic area |
Study Name |
Recruitment status |
Site Investigator |
| Anaesthetics/Cardiology |
ECHO-NOF III - Look before you leap: How transthoracic ECHOcardiography before Neck Of Femur saves lives in frail older people – The proposed Pragmatic ECHONOF III trial
|
OPEN |
Dr Lisa ZUCCHERELLI |
| Oncology – Non-small cell lung cancer |
KRYSTAL-4 (NCT06875310) -
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer with KRAS G12C Mutation
|
OPEN |
Dr Arman HASANI |
| Oncology – Non-small cell lung cancer |
REZLIENT-2 (NCT05967689) -
An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations
|
OPEN |
Dr Arman HASANI |
| Oncology – Non-small cell lung cancer |
ROSETTA Lung-201 (NCT07361497) -
ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 Study of Pumitamig Monotherapy Compared to Durvalumab in Participants With Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy
|
OPEN |
Dr Arman HASANI |
| Oncology – Non-small cell lung cancer |
ROSETTA Lung-202 (NCT07361510) -
A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With PD-L1 ≥ 50%
|
OPEN |
Dr Arman HASANI |
| Paediatrics – Asthma |
ARIA (NCT05757102) -
A Phase 3, 24-week, randomized, double-blind, parallel-group Bayesian Dynamic Borrowing study comparing the efficacy, safety, tolerability and pharmacokinetics of FF/UMEC/VI with FF/VI in 12-17-year-old participants with inadequately controlled asthma on stable maintenance therapy with ICS/LABA
|
OPEN |
Professor Desiree SILVA |
Research Activity
To read more about the research conducted at Joondalup Health Campus, you can download our Annual Research Reports below: